Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist
: Robert M. Badeau, Miikka-Juhani Honka , Riikka Lautamäki, Murray Stewart , Antti J. Kangas, Pasi Soininen , Mika Ala-Korpela, Pirjo Nuutila
: 2014
: Annals of Medicine
: 46
: 1
: 18
: 23
: 6
: 0785-3890
: 1365-2060
DOI: https://doi.org/10.3109/07853890.2013.853369
Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist
February 2014, Vol. 46, No. 1 , Pages 18-23 (doi:10.3109/07853890.2013.853369)
Robert M. Badeau 1, Miikka-Juhani Honka 1, Riikka Lautamäki 1,2, Murray Stewart 3, Antti J. Kangas 4, Pasi Soininen 4,5, Mika Ala-Korpela 4,5,6,7 & Pirjo Nuutila 1,8
1Turku PET Centre, University of Turku and Turku University Hospital
Read More: http://informahealthcare.com/doi/abs/10.3109/07853890.2013.853369
Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist
February 2014, Vol. 46, No. 1 , Pages 18-23 (doi:10.3109/07853890.2013.853369)
Robert M. Badeau 1, Miikka-Juhani Honka 1, Riikka Lautamäki 1,2, Murray Stewart 3, Antti J. Kangas 4, Pasi Soininen 4,5, Mika Ala-Korpela 4,5,6,7 & Pirjo Nuutila 1,8
1Turku PET Centre, University of Turku and Turku University Hospital
Read More: http://informahealthcare.com/doi/abs/10.3109/07853890.2013.853369
UTU Research Portal